0000000000749911

AUTHOR

Hans Michael Kvasnicka

showing 3 related works from this author

Bone marrow fibrosis and diagnosis of essential thrombocythemia

2009

However, there are serious issues to beraisedconcerningtheauthors’analysisoftheclinicaldata,thecriteriausedtodiagnoseET,andthequantificationoffibrosis.Altogethertheauthors compared a heterogenous patient database, which included311 patients evaluated for presenting features, 299 for response totherapy,361forcomplicationrates,97forprogressionoffibrosis,andfour for reversal of BM fibrosis, so no single cohort with consistentfeatures was described throughout the study of 361 patients. Forexample, for the analysis of progression of fibrosis, only 97 (12%) oftheoriginal809patientsenteredintheUK-PT1trial

Cancer Researchmedicine.medical_specialtyPathologyessential thrombocythemiabusiness.industryEssential thrombocythemiaMEDLINEBone marrow fibrosismedicine.diseasemyeloproliferative neoplasmsOncologyInternal medicineCohortMedicinePatient databasebusinessBone marrow fibrosi
researchProduct

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from pref…

2012

Any study of myeloproliferative neoplasms (MPNs) that lacks adequate clinical input is doomed to cause diagnostic uncertainty and increased controversy. In the paper by Buhr et al. published in Haematologica,[1][1] the authors studied 102 cases of essential thrombocythemia (ET) and early primary

WHO classificationPathologymedicine.medical_specialtyGroup trialPediatricsessential thrombocythemiaEssential thrombocythemiabusiness.industryMEDLINEmyelofibrosisHematologySettore MED/08 - Anatomia Patologicamedicine.diseaseWorld healthmedicine.anatomical_structuremedicineWHO classification; early primary myelofibrosis; essential thrombocythemiaearly primary myelofibrosiBone marrowMyelofibrosisWho classificationbusiness
researchProduct

Increased tumor vascularization is associated with the amount of immune competent PD‑1 positive cells in testicular germ cell tumors

2018

Testicular germ cell cancer in a metastatic state is curable with a cisplatin‑based first line chemotherapy. However, 10‑15% of these patients are resistant to first line chemotherapy and are thus left with only palliative options. Immunotherapies and inhibition of angiogenesis used in multiple types of cancer; however, the molecular context of angiogenesis and immune checkpoints in the development and progression of testicular cancers is still unknown. Therefore, the present study performed tissue micro array based analysis of 84 patients with immunohistochemistry of programmed cell death protein 1 (PD‑1), programmed cell death ligand 1 (PD‑L1) and vascular endothelial growth factor recept…

0301 basic medicineendocrine systemCancer ResearchOncogeneAngiogenesisbusiness.industrymedicine.medical_treatmentCancerImmunotherapyCell cyclemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesismedicineCancer researchCytotoxic T cellddc:610businessTesticular cancerOncology Letters
researchProduct